Sugi Predict

Sugi Predict / Compounds / SCHEMBL708027

SCHEMBL708027

SCHEMBL708027

CC(=O)Oc1cc(C)c2c(c1C)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.72
▸ KMT2A Q03164 2/20 0.72
▸ PDE4A P27815 1/20 0.72
▸ PDE3A Q14432 1/20 0.72
▸ PSEN1 P49768 2/20 0.59
▸ LMNA P02545 3/20 0.59
▸ TTPA P49638 3/20 0.59
▸ MAPT P10636 2/20 0.59
▸ GSTP1 P09211 1/20 0.59
▸ USP2 O75604 1/20 0.59
▸ THRB P10828 1/20 0.59
▸ CYP2C9 P11712 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ GSTO1 P78417 2/20 0.59
▸ PTPN1 P18031 1/20 0.59
▸ NR1I2 O75469 4/20 0.52
▸ ALOX5 P09917 2/20 0.52
▸ AKT1 P31749 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25118491 1.00 MEN1 (0.72) MEN1KMT2APDE4APDE3APSEN1
SCHEMBL705369 0.89 GSTO1 (0.76) MEN1KMT2APDE4APDE3APSEN1
SCHEMBL25080534 0.87 AKT1 (0.65) MEN1KMT2APDE4APDE3APSEN1
SCHEMBL2140283 0.87 PSEN1 (0.73) MEN1KMT2APDE4APDE3APSEN1
SCHEMBL20917306 0.86 GSTO1 (0.73) MEN1KMT2APDE4APDE3APSEN1
SCHEMBL29390266 0.85 MEN1 (0.71) MEN1KMT2APDE4APDE3APSEN1
SCHEMBL708419 0.85 MEN1 (0.71) MEN1KMT2APDE4APDE3APSEN1
SCHEMBL13143679 0.85 MEN1 (0.56) MEN1KMT2APDE4APDE3APSEN1
SCHEMBL25118489 0.84 LMNA (0.69) MEN1KMT2APDE4APDE3APSEN1
SCHEMBL25080860 0.84 LMNA (0.69) MEN1KMT2APDE4APDE3APSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118524840-A EPA-EE nano lipid composition, preparation method and application thereof 中国科学院上海药物研究所 2024-08-20 — — CN claimed
CN-110669255-A Stabilizer compositions containing substituted chroman compounds and methods of use thereof 塞特克技术公司 2020-01-10 — — CN claimed
US-9801913-B2 Barrier layer ATRIUM MEDICAL CORPORATION (US) 2017-10-31 — — US claimed
US-8795703-B2 Stand-alone film and methods for making the same ATRIUM MEDICAL CORPORATION (US) 2014-08-05 — — US claimed
US-8367099-B2 Perforated fatty acid films ATRIUM MEDICAL CORPORATION (US) 2013-02-05 — — US claimed
WO-2010104786-A1 USE OF CRYOGENIC PROCESSING TO OBTAIN A SUBSTANTIALLY-THICKENED FORMULATION ATRIUM MEDICAL CORPORATION (US) 2010-09-16 — — WO claimed
US-20100233231-A1 USE OF CRYOGENIC PROCESSING TO OBTAIN A SUBSTANTIALLY-THICKENED FORMULATION ATRIUM MEDICAL CORPORATION 2010-09-16 — — US claimed
EP-2086605-A2 PERFORATED BIOABSORBABLE OIL FILM AND METHODS FOR MAKING THE SAME Atrium Medical Corporation (US) 2009-08-12 — — EP claimed
WO-2008039308-A2 PERFORATED BIOABSORBABLE OIL FILM AND METHODS FOR MAKING THE SAME ATRIUM MEDICAL CORPORATION (US) 2008-04-03 — — WO claimed
EP-1812022-A2 STAND-ALONE FILM AND METHODS FOR MAKING THE SAME Atrium Medical Corporation (US) 2007-08-01 — — EP claimed
US-20070071798-A1 Perforated bioabsorbable oil film and methods for making the same ATRIUM MEDICAL CORPORATION (US) 2007-03-29 — — US claimed
US-20060088596-A1 Solubilizing a drug for use in a coating ATRIUM MEDICAL CORPORATION (US) 2006-04-27 — — US claimed
US-20060083768-A1 Method of thickening a coating using a drug ATRIUM MEDICAL CORPORATION (US) 2006-04-20 — — US claimed
WO-2006036984-A2 STAND-ALONE FILM AND METHODS FOR MAKING THE SAME ATRIUM MEDICAL CORPORATION (US) 2006-04-06 — — WO claimed
WO-2006036970-A2 METHOD OF THICKENING A COATING USING A DRUG ATRIUM MEDICAL CORPORATION (US) 2006-04-06 — — WO claimed
WO-2006036967-A1 SOLUBILIZING A DRUG FOR USE IN A COATING ATRIUM MEDICAL CORPORATION (US) 2006-04-06 — — WO claimed
US-20060067983-A1 Stand-alone film and methods for making the same ATRIUM MEDICAL CORPORATION (US) 2006-03-30 — — US claimed
WO-2023126026-A9 EPA-EE LIPID NANOCOMPOSITE, FORMULATION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 中国科学院上海药物研究所 2024-09-12 — — WO disclosed
US-20060067976-A1 Formation of barrier layer ATRIUM MEDICAL CORPORATION (US) 2006-03-30 — — US disclosed
US-20060067975-A1 UV cured gel and method of making ATRIUM MEDICAL CORPORATION (US) 2006-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060067975-A1 UV cured gel and method of making PTGES, PTGES2, ALOX5 MEN1 4405/4885KMT2A 3176/4885PDE4A 3210/4885
US-20100233231-A1 USE OF CRYOGENIC PROCESSING TO OBTAIN A SUBSTANTIALLY-THICKENED FORMULATION LIPA, CETP, CPT2 MEN1 2327/4885KMT2A 1477/4885PDE4A 1809/4885
US-20060083768-A1 Method of thickening a coating using a drug ABCB1, SLC10A2, ABCB11 MEN1 700/4885KMT2A 2668/4885PDE4A 1121/4885
US-20060088596-A1 Solubilizing a drug for use in a coating ABCB11, ABCB1, SLC10A2 MEN1 1118/4885KMT2A 3563/4885PDE4A 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.